期刊文献+

尿单核细胞趋化因子-1及γ干扰素诱导蛋白对狼疮肾炎活动性病变的评价 被引量:5

Detection of urinary monocyte chemoattr actant protein-1 and interferon-γ-inducible protein-10 to recognize the disease activity of lupus nephritis
原文传递
导出
摘要 目的 探讨LN患者尿中单核细胞趋化因子(MCP-1)、γy干扰素诱导蛋白(IP-10)水平与临床各项活动性指标的关系及临床意义.方法 选取符合1997年ACR LN分类标准,并排除了原发和其他继发性肾脏病,诊断为LN的患者64例,根据2000年SLEDAI将LN患者分为活动组36例(SLEDAI≥10分)与非活动组28例(SLEDAI<10分),并设立健康对照组(20名),2组中共有37例患者同步接受了肾穿刺检查.收集临床资料、肾脏病理并同步留取尿液标本,ELISA法检测尿标本中MCP-1与IP-10水平.采用t检验、秩和检验、x2检验及Spearman相关性分析进行统计分析.结果 ①活动组尿MCP-1及IP-10水平均显著高于非活动组[672.39 (318.05,2 554.23) pg/ml与152.52,(55.61,330.44 pg/ml),Z=-4.717 P<0.01; (38±19) pg/ml与(22±16)pg/ml,=3.576,P<0.01];②患者尿MCP-1水平与镜下血尿、尿蛋白定量(24 h)、SLEDAI积分及BILAG积分呈正相关(r镜下血尿=0.570,P=0.000;r24hpro=0.569,P=0.000;rSLEDAI =0.600,P=0.000;rBILAG=0.606,P=0.000);与血白蛋白、补体C3水平呈负相关(r白蛋白=-0.587,P<0.000; rC3=-0.564,P=0.000).③尿IP-10水平与尿蛋白定量(24h)、SLEDAI积分及BILAG积分呈正相关(r24hpro=0.305,P=0.018;rSLEDAI=0.334,P=0.009; rBILAG=0.496,P=0.000),与C4水平呈负相关(rC4=-0.301,P=0.016).④活动组33例肾活检肾病理结果:15例为Ⅳ型(47%),6例Ⅲ型(19%),5例Ⅲ+V型(16%),3例V型(9%),2例Ⅳ+V型(6%),2例Ⅱ型(6%),病变以肾小管上皮细胞严重变性为主,其次为肾小球严重的细胞增生.⑤尿MCP-1与“白金耳”样病变呈正相关(r=0.430,P=0.014)、与细胞性新月体呈正相关(r=0.405,P=0.015),与活动性评分(AI)呈正相关(r=0.352,P=0.003);尿IP-10与“白金耳”样病变、细胞性新月体及AI无明显相关性(P>0.05).⑥根据尿MCP-1对判断LN全身活动性的ROC曲线,其特异性75.0%,敏感性83.3%,阳性似然比3.33,ROC下面积0.85±0.05.根据尿Ip-10对判断LN全身活动性的ROC曲线,特异性50.0%,敏感性97.2%,阳性似然比1.94,ROC下面积0.74±0.06.⑦根据尿MCP-1对判断LN肾脏活动性病变的ROC曲线,敏感性100%,特异性45.5%,约登指数0.455,阳性似然比1.83,曲线下面积0.74±0.80.根据IP-10对判断LN肾脏活动性病变的ROC曲线,敏感性73.3%,特异性36.4%,约登指数0.097,阳性似然比1.15,曲线下面积:0.49±0.10.结论 尿MCP-1水平与LN全身活动性病变及肾组织活动性病变均密切相关,可作为一种较好的反映LN活动性病变的无创性生物标志物;尿IP-10水平与LN全身活动性病变相关,但对肾脏活动性病变的诊断价值不如尿MCP-1. Objective In this study,we measured the levels of urinary monocyte chemoattractant (MCP)-1 and interferon-γ-inducible protein (IP-10) and further analyzed their associations with clinical and pathological data in lupus nephritis patients in order to find the non-invasive biomarkers which canpredict disease activity.Methods MCP-1,IP-10,VEGF levels were measured in urine samples from 64 lupus nephritis patients and 20 healthy volunteers.Clinical disease activity was determined by SLEDAI and BILAG scores.The lupus nephritis patients were divided into two groups:active disease group (SLEDAI scores ≥ 10points,n=36) and non-active group (SLEDAI score〈10 points,n=28).Of all patients enrolled,37 patients had a concomitant kidney biopsy performed at the time of urine collection.The predictive performance of uri-nary MCP-1 and IP-10 for renal flare,the Student's t test,Mann-Whitney U test,Chi-square test,and re-ceiver operating characteristic (ROC) curves were constructed for analysis.Results The urinary MCP-1 and urinary IP-10 levels of the active group was significantly higher than that of the non-active group [MCP-1672.39(318.05,2 554.23)pg/ml vs 152.52,(55.61,330.44)pg/ml,Z=-4.717,P〈0.01; IP-10 (38±19) pg/ml vs (22±16) pg/ml,t=3.576 P〈0.01].The level of urinary MCP-1 was positively correlated with the levels of hematuria and 24 hours protein quan-tification,as well as the scores of SLEDAI and BILAG (rbemahuria=0.570,P=0.000; r24hpro=0.569,P=0.000; rSLEDAI=0.600,P=0.000; rBILAG=0.606,P=0.000),and it was also positively correlated with the scores of cellular crescent,wire loop,and AI (rCC=0.405,P=0.015; rwire loop=0.430,P=0.014; rAI=0.352,P=0.003),while nega-tively correlated with the level of C3 and plasma albumin (rc3=-0.564,P=0.000; ralb=-0.587,P=0.000).It had no correlation with the scores of wire loop and CI (P〉 0.05).The level of uIP-10 was positively correlated with the protein quantification in 24 hours and the scores of SLEDAI and BILAG (r24hpro=0.305,P=0.018; rSLEDAI=0.334,P=0.009; rSILAG=0.496,P=0.000),while negatively correlated with the level of C4 (rC4=-0.301,P=0.016).The R0C curve of uMCP-1 to predict the activity of SLE showed that its specificity was 75.0%,sensitivity was 83.3%,and the area under the ROC curve was 0.85±0.05.The ROC curve of urinary IP-10 to predict the activity of SLE showed that its specificity was 50.0%,sensitivity was 97.2%,its area under the ROC curve was 0.74±0.06.The ROC curve of urinary MCP-1 to predict renal flare shows that its specificity was 45.5%,its sensitivity was 100%,and the area under the ROC curve was 0.74±0.80.The ROC curve of urinary IP-10 to predict renal flare showed that its specificitywas 36.4%,its sensitivity was 73.3%,and its area under the ROC curve was 0.49 ±0.10.Conclusion Urinary MCP-1 and urinary IP-10 predict renal flare in patients with lupus nephritis.Furthermore,urinary MCP-1 is a more specific and sensitive forecaster of renal flare in patients with a history of lupus nephritis than urinary IP-10.
作者 严小倩 鲁盈
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2014年第11期747-751,I0002,共6页 Chinese Journal of Rheumatology
基金 国家自然科学基金(H2902)
关键词 狼疮肾炎 单核细胞化学吸引蛋白质类 趋化因子CXCL10 CHEMOKINE CXCL10 Lupus nephritis Monocyte chemoattractant proteins
  • 相关文献

参考文献12

  • 1王海燕.肾脏病学[M].2版.北京:人民卫生出版社,2008:2331-2332.
  • 2Chan RW,Lai FM,Li EK,et al.Intrarenal cytokine gene expression in lupus nephritis[J].Ann Rheum Dis,2007,66:886-892.
  • 3Rovin BH,Song H,Birmingham DJ,et al.Urinary chemokines as biomarkers of human systemic lupus erythematosus activity[J].J Am Soc Nephrol,2005,16:467-473.
  • 4Singh RG,Usha,Rathore SS,et al.Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare[J].Lupus,2012,21:1214-1218.
  • 5Abujam B,Cheekatla SS,Aggarwal A.Urinary CXCL-10/IP-10and MCP-1 as markers to assessactivity of lupus nephritis[J].Lupus,2013,22:614-623.
  • 6王君,丁洁,管娜,范青锋.肾脏病患者尿液中三种分子的检测及其与肾小球新月体病变的关系[J].中华肾脏病杂志,2007,23(1):18-22. 被引量:6
  • 7王春燕,刘东伟,刘章锁.狼疮性肾炎患者尿蛋白量与肾脏病理改变相关性研究[J].大连医科大学学报,2008,30(6):533-535. 被引量:2
  • 8Kiani AN,Johnson K,Chen C,et al.Urine osteopmtegerin and monocyte chemoattractant protein-1 in lupus nephritis[J].J Rheumatol,2009,36:2224-2230.
  • 9Lee EY,Lee ZH,Song YW.CXCL10 and autoimmune disease[J].Autoimmun,2009,8:379-383.
  • 10Kong KO,Tan AW,Thong BY,et al.Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus[J].Clin Exp Immunol,2009,156:134-140.

二级参考文献24

  • 1顾越英,叶霜.狼疮肾炎病理分型新进展的启示[J].中华风湿病学杂志,2004,8(9):513-514. 被引量:31
  • 2Weening JJ, D' Agati VD, Schwartz MM, et al. Classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. J Am Soc Nephrol, 2004,15 : 241 - 250.
  • 3Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis:contribution of renal histologic data [J]. Am J Med, 1983, 75:382 -391.
  • 4Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria[J]. Kidney Int, 2003, 63:2254-2261.
  • 5D' Amico G, Bazzi C. Pathophysiology of proteinuria [ J ]. Kidney Int, 2003, 63:809-825.
  • 6Tencer J, Bakoush O, Torffvit O. Diagnostic and prognostic significance of proteinuria selectivity index in glomerular diseases[J]. Clin Chim Acta, 2000, 297:73 - 83.
  • 7Hill GS, Delahousse M, Nochy D, et al. Proteinuria and tubulointerstitial lesions in lupus nephritis[ J]. Kidney Int, 2001, 60 : 1893 - 903.
  • 8Tang S, Lai K, Sacks S. Role of complement in tubulointerstitial injury from proteinuria [ J ]. Kidney Blood Press, 2002, 25:120 126.
  • 9Hsu SI, Couser WG.. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors[ J]. J Am Soc Nephrol,2003, 14 :S186 - 191.
  • 10Birn H, Christensen EI. Renal albumin absorption in physiology and pathology [ J ]. Kidney Int, 2006, 69 : 440 - 449.

共引文献20

同被引文献37

  • 1Mok C C, Yap D Y, Navarra S V, et al. Overview of lupus ne- phritis management guidelines and perspective from Asia[J].Nephrology (Carlton), 2014, 19 (1): 11-20.
  • 2Antonelli A, Ferrari S M, Giuggioli D, et al. Chemokine (C-X- C motif) ligand (CXCL) 10 in autoimmune diseases [J]. Au- toimmunRev, 2014, 13 (3): 272-280.
  • 3Seret G, Le-Meur Y, Renaudineau Y, et al. Mesangial cell-spe- cific antibodies are central to the pathogenesis of lupus nephritis[J].Clin Dev Immunol, 2012, 20 (12): 579-670.
  • 4Groom J R, Luster A D. CXCR3 ligands: redundant, collabora- tive and antagonistic functions [J]. Immunol Cell Biol, 2011, 89 (2):207-215.
  • 5Teramoto K, Negoro N, Kitamoto K, et al. Microarray analy- sis of glomerular gene expression in routine lupus nephritis [J]. J PharmaeolSci, 2008, 106 (1): 56-67.
  • 6Van-Raemdonck K, Van-den-Steen P E, Liekens S, et al. CX- CR3 ligands in disease and therapy [J].Cytokine Grow~th Fac torRev, 2015, 26 (3):311-327.
  • 7Marie M A, Abu-Khalil R E, Habib H M, et al. Urinary CX- CL10: a marker of nephritis in lupus patients [J]. Reumatis- mo, 2014, 65 (6): 292-297.
  • 8Tsai K D, Chen W, Wang S H, et al. Downregulation of con- nective tissue growth factor by LPS/IFN-~'-induced nitric oxideis reversed by aristolochic acid treatment in glomerular mesang ial cells via STAT-la and NF-~B signaling[J].Chem Biol In teraet, 2014, 2 (10): 86-95.
  • 9Kanapathippillai P, Hedherg A, Fenton C G, et al. Nueleo- somes contribute to increase mesangial cell chemokine expres- sion during the development of lupus nephritis[J]. Cytokine, 2013, 62 (2): 244-252.
  • 10Stark G R, Darnell JE Jr. The JAK-STAT pathway at twenty [J]. Immunity, 2012, 36 (4): 503-514.

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部